Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC.
Status:
Recruiting
Trial end date:
2025-11-28
Target enrollment:
Participant gender:
Summary
Aim of this phase 2 study is to evaluate the safety and the efficacy of the combination of
induction chemotherapy plus durvalumab followed by reduced-dose hypo-fractionated thoracic RT
(concurrent with durvalumab) and durvalumab maintenance for stage 3 unresectable NSCLC
patients candidate to sequential chemo-RT.